Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(17))
-URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(19))
-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(25))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Name:	us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Commitments and Contingencies (Details) $ in Millions				9 Months Ended
Commitments and Contingencies (Details) $ in Millions	Jun. 16, 2021 USD ($)	Nov. 10, 2019 plaintiff	Jun. 20, 2017 patent	Sep. 30, 2022 USD ($)
Commitments and Contingencies
Purchase commitments				$ 31.3
Payments on derecognition of lease components	$ 1.1
Number of patents in salt and polymorph patent family \| patent			2
Number of opponents \| plaintiff		1
Number of years regulatory exclusivity in Europe				10 years
Number of years possible additional regulatory exclusivity				1 year